Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the <scp>J‐ROCK</scp> study-Reference-Cited by-同舟云学术

Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study

Published:2022-08-26 Issue:9 Volume:29 Page:1061-1070
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Uemura Hirotsugu¹^ORCID,Matsumoto Rikiya²,Mizokami Atsushi³,Miyake Hideaki⁴,Uemura Hiroji⁵,Matsuyama Hideyasu⁶,Nakamura Kazuyoshi⁷,Saito Kazutaka⁸,Kawakita Mutsushi⁹,Takeshita Hideki¹⁰,Koroki Yosuke¹¹^ORCID,Ono Shintaro¹¹,Murota Maiko¹²,Ito Miku¹¹^ORCID,Kamoto Toshiyuki¹³^ORCID,Fujimoto Kiyohide¹⁴^ORCID

Affiliation:

1. Department of Urology Kindai University Hospital Osaka Japan

2. Department of Urology Chutoen General Medical Center Shizuoka Japan

3. Department of Urology Kanazawa University Hospital Kanazawa Ishikawa Japan

4. Department of Urology Hamamatsu University Hospital Shizuoka Japan

5. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan

6. Department of Urology Yamaguchi University Hospital Yamaguchi Japan

7. Department of Urology Kimitsu Chuo Hospital Chiba Japan

8. Department of Urology Dokkyo Medical University Saitama Medical Center Saitama Japan

9. Department of Urology Kobe City Medical Center General Hospital Kobe Hyogo Japan

10. Department of Urology Saitama Medical Center, Saitama Medical University Saitama Japan

11. Department of Medical Affairs Janssen Pharmaceutical K.K Tokyo Japan

12. Department of Medical Affairs Operations Global Development, Janssen R&D Tokyo Japan

13. Department of Urology University of Miyazaki Hospital Miyazaki Japan

14. Department of Urology Nara Medical University Hospital Nara Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14993

Reference27 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

3. Recent Trends in the Initial Therapy for Newly Diagnosed Prostate Cancer in Japan

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer;Scientific Reports;2024-01-06

2. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study;European Urology Oncology;2024-01

3. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium;Japanese Journal of Clinical Oncology;2023-10-14

4. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study;World Journal of Urology;2022-12-15

5. Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study;The Prostate;2022-10-31